With increasing knowledge regarding the molecular heterogeneity of BC, the recurrence score (RS) based on the 21-gene expression assay has revolutionized the chemotherapy decision-making in N0 and estrogen receptor-positive (ER+) BC patients (6). This evidence concerns the gene ESR1 and breast cancer.